| |
| |
|
| Insider
Information: |
Labrucherie Gil M |
| Relationship: |
Chief Financial Officer |
| City: |
San Carlos |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
319,155 |
|
|
Indirect Shares
|
94,335 |
|
|
| Direct
Value |
$423,139 |
|
|
|
Indirect Value
|
$383,839 |
|
|
| Total
Shares |
413,490 |
|
|
| Total
Value |
$806,978 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-6.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -181.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Nektar Therapeutics |
NKTR |
SVP, COO & CFO |
2022-05-16 |
312,905 |
2008-11-14 |
0 |
Premium* |
|
|
Rezolute, Inc |
RZLT |
Director |
2022-05-04 |
0 |
2022-05-04 |
53,572 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Chief Financial Officer |
2023-10-04 |
6,250 |
2023-10-04 |
40,763 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
104 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-10-02 |
4 |
AS |
$24.45 |
$2,934,000 |
D/D |
(120,000) |
63,414 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-05-01 |
4 |
AS |
$83.65 |
$2,509,500 |
D/D |
(30,000) |
99,739 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-05-02 |
4 |
AS |
$85.63 |
$2,568,900 |
D/D |
(30,000) |
99,739 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-05-03 |
4 |
AS |
$82.86 |
$2,485,800 |
D/D |
(30,000) |
99,739 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-06-17 |
4 |
AS |
$33.71 |
$842,750 |
D/D |
(25,000) |
127,935 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-07-10 |
4 |
AS |
$34.57 |
$864,250 |
D/D |
(25,000) |
127,935 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-08-14 |
4 |
AS |
$17.79 |
$444,750 |
D/D |
(25,000) |
127,935 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-09-16 |
4 |
AS |
$20.52 |
$513,000 |
D/D |
(25,000) |
152,872 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2019-10-15 |
4 |
AS |
$15.83 |
$395,750 |
D/D |
(25,000) |
227,872 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2019-11-13 |
4 |
AS |
$19.79 |
$494,750 |
D/D |
(25,000) |
227,872 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2020-05-18 |
4 |
AS |
$22.51 |
$128,915 |
D/D |
(5,727) |
247,494 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2020-05-19 |
4 |
AS |
$22.62 |
$45,240 |
D/D |
(2,000) |
245,494 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2020-08-17 |
4 |
AS |
$19.67 |
$122,839 |
D/D |
(6,245) |
239,249 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2020-08-18 |
4 |
AS |
$19.68 |
$39,360 |
D/D |
(2,000) |
237,249 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2020-09-17 |
4 |
AS |
$19.96 |
$39,920 |
D/D |
(2,000) |
235,249 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-02 |
4 |
AS |
$19.97 |
$1,008,629 |
D/D |
(50,000) |
266,973 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-03 |
4 |
AS |
$19.61 |
$980,500 |
D/D |
(50,000) |
266,973 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-04 |
4 |
AS |
$19.81 |
$990,500 |
D/D |
(50,000) |
266,973 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-08-16 |
4 |
AS |
$13.83 |
$108,801 |
D/D |
(7,867) |
243,231 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-08-17 |
4 |
AS |
$13.56 |
$40,680 |
D/D |
(3,000) |
240,231 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-11-16 |
4 |
AS |
$13.16 |
$278,321 |
D/D |
(21,149) |
259,682 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-11-18 |
4 |
AS |
$12.69 |
$38,070 |
D/D |
(3,000) |
256,682 |
0 |
% |
|
| RZLT |
Rezolute, Inc |
Director |
– • – |
2022-05-04 |
4/A |
B |
$3.80 |
$199,998 |
I/I |
52,631 |
53,572 |
2.1 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-11-16 |
4 |
D |
$44.23 |
$296,253 |
D/D |
(6,698) |
76,716 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-08-16 |
4 |
D |
$58.40 |
$479,289 |
D/D |
(8,207) |
113,059 |
0 |
- |
|
104 Records found
|
|
Page 2 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
